[A24-93] Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Addendum to Project A24-46
Last updated 17.10.2024
Project no.:
A24-93
Commission:
Commission awarded on 10.09.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with resectable non-small cell lung cancer with tumour cell PD-L1 expression < 1% at high risk of recurrence; pembrolizumab in combination with platinum-based chemotherapy (neoadjuvant) and subsequent monotherapy (adjuvant)
Added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A24-93_en
| Project no. | Title | Status |
|---|---|---|
| A24-46 | Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V | Commission completed |
| G24-23 | Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Second Addendum to Project A24-46 | Commission completed |
Federal Joint Committee (G-BA)
17.10.2024 A G-BA decision was published.
G-BA documents on this decision